Journal of Molecular and Cellular Cardiology
Volume 49, Issue 1 , Pages 88-94 , July 2010

Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice

  • John M. Streicher

      Affiliations

    • Departments of Anesthesiology, Physiology and Medicine, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Kenichiro Kamei

      Affiliations

    • Biological Chemistry and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Tomo-o Ishikawa

      Affiliations

    • Biological Chemistry and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Harvey Herschman

      Affiliations

    • Biological Chemistry and Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • Molecular Biology Institute, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • ,
  • Yibin Wang

      Affiliations

    • Departments of Anesthesiology, Physiology and Medicine, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • Molecular Biology Institute, David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA 90095, USA
    • Corresponding Author InformationCorresponding author. 650 Charles E. Young Drive, Room 569, CHS, Department of Anesthesiology, David Geffen School of Medicine, UCLA, Los Angeles, CA 91301, USA. Tel.: +1 310 206 5197; fax: +1 310 206 5907.

Received 26 October 2009 ,Revised 29 January 2010 ,Accepted 30 January 2010.

References 

  1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145–182
  2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. Nov 23 2000;343(21):1520–15282 p following 8
  3. Chang H, Hanawa H, Liu H, Yoshida T, Hayashi M, Watanabe R, et al. Hydrodynamic-based delivery of an interleukin-22–Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol. Sep 15 2006;177(6):3635–3643
  4. Grandel U, Hopf M, Buerke M, Hattar K, Heep M, Fink L, et al. Mechanisms of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation. Aug 2 2005;112(5):691–698
  5. Takahashi T, Zhu SJ, Sumino H, Saegusa S, Nakahashi T, Iwai K, et al. Inhibition of cyclooxygenase-2 enhances myocardial damage in a mouse model of viral myocarditis. Life Sci. Nov 26 2005;78(2):195–204
  6. Abbate A, Salloum FN, Ockaili RA, Fowler AA, Biondi-Zoccai GG, Straino S, et al. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol. 2007;416–418
  7. Timmers L, Sluijter JP, Verlaan CW, Steendijk P, Cramer MJ, Emons M, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation. Jan 23 2007;115(3):326–332
  8. Leung WK, Wu KC, Wong CY, Cheng AS, Ching AK, Chan AW, et al. Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis. Aug 2008;29(8):1648–1654
  9. Mayoral R, Molla B, Flores JM, Bosca L, Casado M, Martin Sanz P. Constitutive expression of cyclooxygenase 2 transgene in hepatocytes protects against liver injury. Biochem J. Dec 15 2008;416(3):337–346
  10. Xiang Z, Thomas S, Pasinetti G. Increased neuronal injury in transgenic mice with neuronal overexpression of human cyclooxygenase-2 is reversed by hypothermia and rofecoxib treatment. Curr Neurovasc Res. 2007 Nov;4(4):274–279
  11. Wang X, Colby JK, Rengel RC, Fischer SM, Clinton SK, Klein RD. Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces the expression of immune- and cell proliferation-related genes. Mol Carcinog. 2009 Jan;48(1):1–13
  12. Inserte J, Molla B, Aguilar R, Traves PG, Barba I, Martin-Sanz P, et al. Constitutive COX-2 activity in cardiomyocytes confers permanent cardioprotection Constitutive COX-2 expression and cardioprotection. J Mol Cell Cardiol. Feb 2009;46(2):160–168
  13. Kamei K, Ishikawa TO, Herschman HR. Transgenic mouse for conditional, tissue-specific Cox-2 overexpression. Genesis. Apr 2006;44(4):177–182
  14. Chen J, Kubalak SW, Minamisawa S, Price RL, Becker KD, Hickey R, et al. Selective requirement of myosin light chain 2v in embryonic heart function. J Biol Chem. Jan 9 1998;273(2):1252–1256
  15. Garvey W. Modified elastic tissue—Masson trichrome stain. Stain Technol. Jul 1984;59(4):213–216
  16. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. Dec 15 1991;108(2):193–199
  17. Mendez M, LaPointe MC. PGE2-induced hypertrophy of cardiac myocytes involves EP4 receptor-dependent activation of p42/44 MAPK and EGFR transactivation. Am J Physiol Heart Circ Physiol. May 2005;288(5):H2111–H2117
  18. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev. Dec 2007;12(3–4):331–343
  19. Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S, et al. COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res. May 30 2003;92(10):1153–1161
  20. Streicher JM, Wang Y. The role of COX-2 in heart pathology. Cardiovasc Hematol Agents Med Chem. Jan 2008;6(1):69–79
  21. Wacker MJ, Best SR, Kosloski LM, Stachura CJ, Smoot RL, Porter CB, et al. Thromboxane A2-induced arrhythmias in the anesthetized rabbit. Am J Physiol Heart Circ Physiol. Apr 2006;290(4):H1353–H1361
  22. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Tanaka H, Isobe M. A cyclooxygenase-2 inhibitor alters Th1/Th2 cytokine balance and suppresses autoimmune myocarditis in rats. J Mol Cell Cardiol. May 2006;40(5):688–695
  23. Adams JW, Migita DS, Yu MK, Young R, Hellickson MS, Castro-Vargas FE, et al. Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem. Jan 12 1996;271(2):1179–1186
  24. Shinmura K, Tamaki K, Sato T, Ishida H, Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol. May 2005;288(5):H2093–H2101
  25. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. Oct 1997;81(4):627–635
  26. Lien YC, Lin SM, Nithipongvanitch R, Oberley TD, Noel T, Zhao Q, et al. Tumor necrosis factor receptor deficiency exacerbated adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection. Mol Cancer Ther. Feb 2006;5(2):261–269

PII: S0022-2828(10)00034-9

doi: 10.1016/j.yjmcc.2010.01.021

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 1 , Pages 88-94 , July 2010

Article Tools

* Image Usage & Resolution